

New order for customized GoBio to American gene therapy market

Today, Bio-Works has confirmed a new order worth 3.4 million SEK for GoBio prepacked columns to the American market. The order is planned for delivery during the first half of the year. The order is for a unique version of GoBio, specially developed for the purification of plasmids, a precursor used in the manufacture of viral vectors for gene therapy applications. The customization allows the user to achieve a result which would not be possible with a standard solution.

"We see that more and more customers are realizing that they can improve their results by using a more customized purification product, and here Bio-Works can play an important role," says Jonathan Royce, CEO at Bio-Works.

"We have the technical competence and flexibility to quickly be able to develop niche products for our customers—products which can truly be game changing. For us as a company, customization means that we can develop products for our portfolio of tools which can help other customers with similar challenges. It's a win-win."

GoBio is Bio-Works' new product line av "prepacked" columns, an offering within the rapidly growing category of "plug and play" solutions. The term "prepacked" encompasses turnkey solutions which enable the user to skip the time-consuming and technically-complicated operations involved in manually packing a chromatography column.

This order is a follow-up to the order which was announced on 12 May 2022 to an American manufacturer of plasmids.

Contacts

For more information, please visit the Bio-Works homepage at www.bio-works.com or contact: Jonathan Royce, CEO, e-mail: jonathan.royce@bio-works.com, phone: +46 70 1434143.

About Bio-Works

Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works' next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North ("BIOWKS"), and FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se, is appointed Certified Adviser. For more information, www.bio-works.com.

This information is information that Bio-Works Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-01-20 09:20 CET.

Attachments

[New order for customized GoBio to American gene therapy market](#)